[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iron-deficiency-anemia-ida\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iron-deficiency-anemia-ida":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,83,117,143,172],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100646457","phase-3-a-study-to-test-the-non-inferiority-of-ferric-bepectate-iv-against-ferric-carboxymaltose-in-patients-with-iron-deficiency-anemia-100646457",false,"NCT07687784","A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia","A Multicentre, Prospective, Randomized, Active-Controlled, Open-Label, Phase III Study to Test the Non-Inferiority of Intravenous Injection of Ferric Bepectate IV Injection Compared to Ferric Carboxymaltose for Treatment of Patients With Iron Deficiency Anaemia (IDA)","Inclusion Criteria:\n\n1. Male or female patient at least 18 years old at the time of screening\n2. Patients with general iron deficiency anaemia IDA\n3. Patients with serum ferritin levels ≤40 ng\u002FmL inclusive\n4. Patients with haemoglobin (Hb) levels \\\u003C10 g\u002FdL\n5. Patients ≥ 35 kg body weight\n6. The patient has adequate hepatic and renal function defined as a serum aspartate aminotransferase or alanine aminotransferase level that are no more than 3 times the upper limit of the normal range, a serum bilirubin level that is no more than 2 times the upper limit of the normal range and a serum creatinine level of less than 2 mg\u002FdL.\n7. The patient is able to understand the protocol and provides informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding patients\n2. Female patients not willing to use a safe method of contraception (PEARL index \\\u003C1) for the full study (screening - V5).\n3. Severe physical inability, e.g., ASA physical status IV or V.\n4. Non-iron deficiency anaemia, e.g., known Vitamin B12 or folate deficiency, hemoglobinopathy, or unexplained anaemia.\n5. Patients with life-threatening anaemia, defined as Hb \\\u003C 6.5 g\u002FdL.\n6. Patient is expected to require a blood transfusion within the study period or has had a blood transfusion within the 30 days prior screening.\n7. Anticipated medical need for erythropoiesis-stimulating agents during the study period (screening - V5).\n8. Patients with hemodynamic instability due to any ongoing bleeding. Absence of ongoing bleeding will be confirmed either by decision of two independent physicians or by removal of drainage whichever occurs earlier in routine care.\n9. Patient has undergone a surgical procedure during the 30 days prior to screening, and\u002For is expected to undergo a surgical procedure during the study period (screening - V5).\n10. Patients with any contraindication to the investigational products, e.g.,\n\n    1. known sensitivity to iron or an ingredient of the investigational products,\n    2. significant history of systemic allergic reactions,\n    3. hemochromatosis, thalassemia or TSAT \\>50% as indicator of iron overload,\n    4. acute or chronic intoxication,\n    5. infection (patient on non-prophylactic antibiotics),\n    6. chronic liver disease and\u002For screening ALT or AST above three times the upper limit of the normal range.\n    7. chronic kidney disease, defined as GFR \\\u003C30 mL\u002Fmin.\n11. Primary hematologic disease.\n12. Drug or alcohol abuse according to WHO definition.\n13. Potentially unreliable patients, and those judged by the investigator to be unsuitable for the study.\n14. Current or previous participation in another clinical trial during the last 90 days before screening.\n15. Exclusion criteria according to SmPC of Ferric Carboxymaltose.\n16. The following concomitant treatments prescribed by a physician for non-iron deficiency anaemia (e.g., known vitamin B12 or folate deficiency), hemoglobinopathy, or unexplained anaemia are not allowed during the study and 24 weeks before screening: Erythropoiesis-stimulating agents, vitamin B12, Folic acid or other I.V. or oral iron products.\n17. Estimated life expectancy of \\\u003C6 months or, for cancer patients, an Eastern Cooperative Oncology Group performance status \\>1","ALL","18 Years",{"count":19,"type":20},1366,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this clinical trial is to see if a new intravenous iron formulation (Ferric Bepectate IV Injection) can treat adult patients with iron deficiency anemia (IDA) by increasing blood hemoglobin (Hb) as an established formulation (Ferric carboxymaltose). It will also learn about the safety of Ferric Bepectate IV Injection. The main questions it aims to answer are:\n\n* Does hemoglobin increase by the same amount 6 weeks after each treatment?\n* What medical problems do participants have when being treated with the drug? Researchers will compare single dose treatment plans of Ferric Bepectate to double dose treatment plans of both Ferric Bepectate and Ferric carboxymaltose.\n\nParticipants and researchers will know which drug they are being provided (open-label). Participants will visit the clinic 5 times over 6 weeks for checkups, blood tests and questionaries. The first two visits will be seven days apart and include the two doses of iron treatment.",[26],"Iron Deficiency Anemia (IDA)",[28,29,30,31,32,33],"Iron infusion","Non-inferiority","Ferric bepectate","Ferric carboxymaltose","Ferinject","Injectafer","NOT_YET_RECRUITING","2026-08-18",{"date":37,"type":38},"2026-08-20","ACTUAL",{"date":40,"type":20},"2026-12",{"date":42,"type":20},"2028-07",{"name":44,"class":45},"AFT Pharmaceuticals, Ltd.","INDUSTRY",13,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100652514","phase-4-ferric-carboxymaltose-versus-iron-sucrose-for-iron-deficiency-anemia-after-radical-gastrectomy-for-gastric-cancer-100652514","NCT07772453","Ferric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia After Radical Gastrectomy for Gastric Cancer","Ferric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia After Radical Gastrectomy for Gastric Cancer: A Multicenter Open-Label Randomized Controlled Trial","IRIS","Inclusion Criteria:\n\n* Age 18 to 75 years, sex male or female, and body weight ≥ 50 kg.\n* Histopathologically confirmed gastric cancer (TNM stage I-III according to the AJCC 8th edition) and have undergone curative (R0) resection.\n* Postoperative anemia defined as a hemoglobin (Hb) level \\\u003C 100 g\u002FL within 24 hours after surgery (i.e., on postoperative day 1), meeting the diagnostic criteria for postoperative anemia in gastric cancer patients.\n* Evidence of iron deficiency, as indicated by:\n* serum ferritin \\\u003C 30 μg\u002FL, or\n* serum ferritin \\\u003C 100 μg\u002FL and transferrin saturation (TSAT) \\\u003C 20%, confirming iron-deficiency anemia.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n* Adequate hepatic, renal, and coagulation function, defined as:\n* ALT and AST ≤ 2.5 × upper limit of normal (ULN),\n* serum creatinine ≤ 1.5 × ULN,\n* prothrombin time international normalized ratio (INR) ≤ 1.5.\n* Estimated life expectancy ≥ 3 months.\n* Voluntary written informed consent and ability to comply with the trial treatment and follow-up procedures.\n\nExclusion Criteria:\n\nNon-iron-deficiency anemia (e.g., hemolytic anemia, thalassemia, megaloblastic anemia, aplastic anemia, tumor-related non-iron-deficiency anemia, etc.) or disorders of hemoglobin synthesis.\n\n* Known hypersensitivity to ferric carboxymaltose, iron sucrose injection, or any of their excipients.\n* Evidence of iron overload (serum ferritin \\> 1000 μg\u002FL) or a history of hemochromatosis.\n* Severe hepatic or renal impairment, defined as:\n* ALT\u002FAST \\> 2.5 × upper limit of normal (ULN),\n* serum creatinine \\> 1.5 × ULN,\n* or coagulopathy (INR \\> 1.5);\n* or active bleeding (e.g., major postoperative anastomotic hemorrhage, intra-abdominal bleeding, etc.).\n* Receipt of oral iron, intravenous iron, or erythropoiesis-stimulating agents (ESAs) \u002F erythropoietin (EPO) within the past 3 months prior to screening.\n* Concurrent other malignancies, severe cardiovascular disease (e.g., heart failure, history of myocardial infarction, severe arrhythmias), uncontrolled infectious disease (e.g., sepsis), or immunodeficiency disorders.\n* Pregnant or breastfeeding women, or women who plan to become pregnant during the trial period.\n* Inability to comply with the treatment and follow-up procedures (e.g., due to cognitive impairment, psychiatric disorders), or any other condition that, in the investigator's judgment, would render the participant unsuitable for inclusion in the study.","75 Years",{"count":57,"type":20},160,[59],"PHASE4","This is a multicenter, open-label, randomized controlled trial. A total of 160 patients with iron-deficiency anemia after radical gastrectomy for gastric cancer will be enrolled and randomly assigned in a 1:1 ratio. Subjects in the experimental group will receive a single-dose intravenous ferric carboxymaltose on postoperative day 1, while the control group will receive multiple intravenous infusions of iron sucrose to achieve an identical total iron dose. All participants will follow standardized postoperative nutritional support and transfusion criteria. The primary endpoint is the hemoglobin response rate at postoperative week 3. Secondary endpoints include changes in hemoglobin and iron-related biomarkers, transfusion requirements, postoperative complications, functional recovery, and the incidence of adverse events. This study aims to compare the efficacy and safety of the two intravenous iron preparations and provide evidence for optimal postoperative iron supplementation for gastric cancer surgical patients.",[62,26,63,64],"Gastric Cancer (GC)","Post-Operative Anemia","Radical Gastrectomy",[66,67,68,69,70,71,72],"Ferric Carboxymaltose","Iron Sucrose","Intravenous Iron Supplementation","Gastrectomy","Postoperative Iron Deficiency","Gastric Cancer Surgery","Iron-deficiency Anemia","2026-08-16",{"date":75,"type":38},"2026-08-19",{"date":77,"type":20},"2026-08",{"date":79,"type":20},"2028-03",{"name":81,"class":82},"Zhaojian Niu,MD","OTHER",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":90,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":94,"conditions":95,"keywords":100,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":116},"100635749","phase-3-comparison-of-ferrous-salt-vs-liposomal-iron-in-adult-women-with-iron-deficiency-anemia-100635749","NCT07556731","Comparison of Ferrous Salt vs. Liposomal Iron in Adult Women With Iron-Deficiency Anemia","IDA","Inclusion Criteria:\n\n* Female patients of reproductive age (15 to 49 years) with a diagnosis of iron-deficiency anemia secondary to dysfunctional uterine bleeding.\n* Patients with iron-deficiency anemia who are treatment-naïve or whose last administration of iron therapy, either oral or parenteral, occurred at least three months prior to enrollment and who continue to have anemia.\n* Patients with a functional oral route.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Patients with abnormal uterine bleeding secondary to cancer\n* Severe intolerance to iron supplementation\n* Patients with gastritis or chronic use of proton pump inhibitors\n* Concomitant treatment with dietary supplements rich in calcium, magnesium, or zinc\n* Patients with endocrine disorders (hypothyroidism, hyperthyroidism)\n* Uncontrolled type 2 diabetes mellitus\n* Associated gastrointestinal bleeding\n* Patients with esophageal disorders","FEMALE",{"count":92,"type":20},100,[23],"The goal of this study is to compare ferrous salt and liposomal iron for the treatment of iron-deficiency anemia in adult women. The study will also evaluate how well each treatment is tolerated.\n\nThe main questions this study aims to answer are:\n\nDoes liposomal iron increase hemoglobin levels as effectively as ferrous salt?\n\nAre there differences in side effects, especially gastrointestinal symptoms, between the treatments?\n\nDoes dosing ferrous salt every other day improve tolerance compared to daily dosing?\n\nResearchers will compare three oral iron treatment strategies to determine which approach provides the best balance between effectiveness and tolerability.\n\nParticipants will:\n\nBe adult women diagnosed with iron-deficiency anemia\n\nBe randomly assigned to one of three groups:\n\nDaily ferrous salt Ferrous salt taken every other day Daily liposomal iron Take the assigned iron treatment for 3 months Have blood tests at the beginning and end of the study to measure hemoglobin and iron levels Report any side effects or intolerance during treatment",[96,97,98,99],"Iron-deficiency Anemia (IDA)","Hemoglobin","Iron Deficiencies","Adverse Effect",[101,102,103,104,105],"Iron-deficiency anemia treatment comparision","Oral iron dosing","Liposomal iron","Iron replacement therapy","ferritin","2026-04-22",{"date":108,"type":38},"2026-04-29",{"date":110,"type":20},"2026-05-01",{"date":112,"type":20},"2027-07-01",{"name":114,"class":115},"Hospital General de Mexico","OTHER_GOV",1,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":90,"minAge":17,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":21,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":116},"100553932","phase-4-oral-iron-supplementation-on-alternate-vs-consecutive-days-for-iron-deficiency-anemia-in-pregnancy-100553932","NCT06492512","Oral Iron Supplementation on Alternate vs. Consecutive Days for Iron Deficiency Anemia in Pregnancy","Inclusion Criteria:\n\n* Pregnant patients will be enrolled at less than 30 weeks gestational age (GA) with laboratory confirmed IDA (as defined by hemoglobin under 10.5 g\u002FdL, as well as ferritin under 15 mcg\u002FL)\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years old, patients who have severe IDA that requires blood transfusion or IV iron infusion, patients who have other known hemoglobinopathy (such as thalassemia or sickle cell anemia) or anemia of different mechanism (such as vitamin B12 or folate deficiency), patients with ulcerative colitis, Crohn's disease, gastric ulcers, patients who have previously undergone gastric bypass surgery, patients who experience admission for antepartum bleed, have been diagnosed with abnormal placentation (i.e., placenta previa, placenta accreta, placenta increta or percreta)","45 Years",{"count":125,"type":20},120,[59],"This will be a randomized clinical trial. Enrolled subjects will be randomized (1:1) into two study arms to receive either daily (Group 1) or alternate day (Group 2) supplementation with one oral pill containing ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill.",[96,129],"Pregnancy",[131,132],"Iron-deficiency anemia (IDA)","Iron-deficiency anemia (IDA) during gestation","RECRUITING","2026-04-21",{"date":136,"type":38},"2026-04-24",{"date":138,"type":38},"2025-05-27",{"date":140,"type":20},"2029-07-30",{"name":142,"class":82},"Southern Illinois University",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":90,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":153,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":171},"100616681","phase-4-efficacy-and-tolerability-of-sucrosomial-iron-vs-ferric-maltol-in-iron-deficient-women-100616681","NCT07308769","Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient Women","A Prospective, Open-Label, Randomized, Interventional Study to Evaluate the Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient Women","SID-WOMEN","Inclusion Criteria:\n\n* Female participants ≥ 18 years\n* Mild anemia (11.0 ≤ Hb \\\u003C 12 g\u002FdL) or moderate anemia (8.0 \\\u003C Hb \\\u003C 11 g\u002FdL)\n* Signed informed consent\n\nExclusion Criteria:\n\n* Use of iron-containing drugs or supplements within 1 month prior to screening\n* Psychiatric disorders interfering with consent or compliance\n* Active cancer (except fibroids and polyps)\n* Pregnant or breastfeeding women\n* Participation in another interventional study\n* History of poor adherence or inability to comply\n* Use of erythropoietin within 3 months prior to screening\n* Need for blood transfusion or IV iron (per investigator judgment)\n* Severe active IBD (HBI \\> 16 for Crohn; CAI \\> 12 for ulcerative colitis)\n* Previous bariatric surgery\n* Alcohol abuse\n* Hemochromatosis or iron overload syndromes\n* Hereditary anemias (including thalassemia)\n* Known hypersensitivity to study product ingredients",{"count":152,"type":20},146,[59],"This study aims to compare two oral iron treatments, Sucrosomial® Iron and Ferric Maltol, in women with mild to moderate iron deficiency anemia. Many patients experience gastrointestinal side effects or poor tolerability with traditional iron supplements, which may limit adherence. Participants will be randomly assigned to receive either Sucrosomial® Iron or Ferric Maltol for 12 weeks. The primary objective is to determine whether Sucrosomial® Iron is as effective as Ferric Maltol in normalizing hemoglobin levels.",[156,26],"Anemia",[158,159,160,161],"Iron Deficiency","Iron Deficiency Anemia","Mild to Moderate Anemia","anemia in women","2026-03-20",{"date":164,"type":38},"2026-03-23",{"date":166,"type":38},"2025-12-11",{"date":168,"type":20},"2026-10",{"name":170,"class":45},"Pharmanutra S.p.a.",7,{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":182,"phases":4,"briefSummary":183,"conditions":184,"keywords":189,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":198,"leadSponsor":200,"locationsCount":116},"100565050","patient-blood-management-in-patients-scheduled-for-cardiac-surgery-100565050","NCT06637137","Patient Blood Management in Patients Scheduled for Cardiac Surgery","Patient Blood Management in Cardiac Surgical Patients: the ICARUS-2 Study","ICARUS-2","Inclusion Criteria:\n\n\\- all adult patients scheduled for elective cardiac surgery\n\nExclusion Criteria:\n\n* pregnancy\n* dyalisis\n* patient's refusal",{"count":181,"type":20},464,"OBSERVATIONAL","The ICARUS 2 study has the general objective of collecting data in patients undergoing cardiac surgery; in our centre, in order to optimize and improve hemoglobin values, a team of haematologists, assisted by cardio anesthetists and cardiac surgeons, will evaluate the blood tests of patients scheduled for elective cardiac surgery in order to correct any states of hypoferritinemia (low iron in the blood) to promote recovery from blood losses related to cardiac surgery. This objective is strongly encouraged by the good use of blood programs currently in force at our foundation.\n\nIn particular, the research presented here intends to demonstrate a reduction in the number of intra- and post-operative transfusions.",[156,185,186,26,187,188],"Anemia, Iron-Deficiency","Iron Deficiency Anemia Treatment","Cardiac Surgical Patients","Blood Loss, Surgical",[190,191,192,193],"iron","anemia","cardiac surgery","patient blood management","2025-02-24",{"date":196,"type":38},"2025-02-26",{"date":194,"type":38},{"date":199,"type":20},"2027-02-28",{"name":201,"class":82},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]